LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aandelen Lijst・Prothena Corp PLC

Prothena Corp PLC

Gesloten

SectorGezondheidszorg

10.31 -4.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.19

Max

10.75

Belangrijke statistieken
By Trading Economics
Inkomsten	89M -37M
Verkoop	-2M 2.4M
Winstmarge	-1,513.085
Werknemers	163
EBITDA	16M -36M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+93.85% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	10M 578M
Vorige openingsprijs	14.4
Vorige sluitingsprijs	10.31

Nieuwssentiment

By Acuity

42%

58%

156 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

N/A / 7.35 Steun & Weerstand

Prothena Corp PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 dec 2025, 22:13 UTC

Winsten

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dec 2025, 21:40 UTC

Winsten

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dec 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dec 2025, 16:57 UTC

Belangrijke Marktbewegers

Clear Secure Rises on Medicare Identity Verification Contract

9 dec 2025, 23:46 UTC

Marktinformatie

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dec 2025, 23:46 UTC

Acquisities, Fusies, Overnames

Legend Holdings Stake in Lenovo Now at 32.34%

9 dec 2025, 23:45 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dec 2025, 23:44 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dec 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dec 2025, 22:42 UTC

Winsten

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 21:48 UTC

Marktinformatie

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dec 2025, 20:28 UTC

Marktinformatie

Oil Futures Decline for Second Straight Session -- Market Talk

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Reports Voting Results From Special Meeting of Hldrs

9 dec 2025, 20:26 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dec 2025, 20:21 UTC

Marktinformatie

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dec 2025, 19:52 UTC

Winsten

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dec 2025, 19:17 UTC

Winsten

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 dec 2025, 17:11 UTC

Winsten

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Prothena Corp PLC Prognose

Koersdoel

By TipRanks

93.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.8 USD 93.85%

Hoogste 36 USD

Laagste 8 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Prothena Corp PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Prothena Corp PLC - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 7.35Steun & Weerstand

All events are bearish.

Sentiment

By Acuity

156 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.